Rextovy (Naloxone HCl) Patent Expiration, LOE Window & CMS Spending

Rextovy (Naloxone HCl) by Amphastar Pharmaceuticals: FDA Orange Book LOE 2026-03-07, 0 AB generics, $8K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmphastar Pharmaceuticals
FDA Application & PathwayN208969 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-03-07
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$8K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$8K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel